Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Short Interest Update

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 744,500 shares, a drop of 32.5% from the January 31st total of 1,103,100 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 7,445.0 days.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Tuesday, December 10th.

Hikma Pharmaceuticals Price Performance

HKMPF stock remained flat at $27.17 on Thursday. The company has a 50 day simple moving average of $26.27 and a two-hundred day simple moving average of $25.39. The company has a current ratio of 1.66, a quick ratio of 0.98 and a debt-to-equity ratio of 0.46. Hikma Pharmaceuticals has a fifty-two week low of $22.33 and a fifty-two week high of $28.92.

Hikma Pharmaceuticals Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, March 21st will be paid a $0.48 dividend. This is a boost from Hikma Pharmaceuticals's previous dividend of $0.47. The ex-dividend date is Friday, March 21st.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.